Chapters

Transcript

Video

Better Cancer Care: Pearls From the Best Studies of 2022

Focusing on blood, breast and lung cancers, our specialists deliver exciting findings from the latest phase III trials. They explain keys to predicting disease progression; illuminate the roles of new therapies, including bispecific antibodies and antibody-drug conjugates; and discuss serious adverse effects, such as cytokine release syndrome and pneumonitis. Learn about T-DXd (now the standard for nonresectable or metastatic HER2), tailoring lung cancer management through neoadjuvant therapies, and more. Bonus: practical considerations for matching patients to treatment plans.

John Muir Health Presenters: 

 
 
 
 

Published

December 16, 2022

Created by

UCSF MedConnection

Related Presenters

Matthew Gubens, MD, MS, FASCO

Matthew Gubens, MD, MS, FASCO

Thoracic medical oncologist

View Full Profile

Andrew Ko, MD

Andrew Ko, MD

Colorectal and gastrointestinal cancer specialist

View Full Profile

Thomas G. Martin, MD

Thomas G. Martin, MD

Hematologist-oncologist

View Full Profile